INSIGHTS ON DRUG DEVELOPMENT

DRUG DEVELOPMENT SOLUTIONS

  • We have experience with monoclonal antibodies, antibody-drug conjugates, and many other molecule types, including highly glycosylated proteins and biosimilars.

  • Catalent’s UpTempo℠ AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current 18-20-month development timeline for drug product in half.

  • KBI’s extensive analytical capabilities help our clients develop lasting solutions to analytical challenges faced during the development of biologics.

  • Our approach is designed to optimize efficiency and accelerate timelines, resulting in up to 40% time savings throughout the early phases of your drug development journey.

  • Improve productivity and cell growth in fed-batch cultures by supplementing the cell culture medium to boost nutrients depleted during culture. HyClone™ Cell Boost™ 1 Supplement provides nutrients such as amino acids and glucose that are suitable for research and bioprocessing applications.